The Medicines Company (leipzig) Gmbh

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Wilex Biotechnology Gmbh

Joerg Stuerzebecher

Torsten Steinmetzer

Andrea Schweinitz

Claudia Reichelt

Alexander Schulze

Friedrich-Alexander Ludwig

Jochen Heinicke

Andreas Van De Locht

Peter Steinmetzer

Anett Soeffing

Silke Nicklisch

Olaf G Wilhelm

Robert Huber

Luis Moroder

Viktor Magdolen

Stefan Sperl

Uwe Jacob

Wolfram Bode

Mohammed Daghish

Nuria Arroyo De Prada

Mohammed Daghisch

Daniel Doennecke

Anne Stuerzebecher

The invention relates to inhibitors of trypsin-like serine proteases, including those of the general formula (IV) which, as well as plasmin, also inhibit plasma kallikrien, and to their use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

Trypsin-like serine protease inhibitors, and their preparation and use

The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.

Urokinase inhibitors, production and use thereof

The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrein, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.

2-(Aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of coagulation factor Xa are provided. The compounds are suitable for the treatment and prophylaxis of cardiovascular and thrombotic events.

2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): 

Highly selective inhibitors of the urokinase plasminogen activator

The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.

Growing community of inventors

Erfurt, Germany

Joerg Stuerzebecher